Your activity: 54 p.v.
< Back
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Dose modification guidelines for cetuximab based upon cutaneous adverse reaction

Dose modification guidelines for cetuximab based upon cutaneous adverse reaction
Severe acneiform rash Initial management Outcome Dose modification
First occurrence Delay infusion 1 to 2 weeks Improvement Continue at 250 mg/m2
No improvement Discontinue cetuximab
Second occurrence Delay infusion 1 to 2 weeks Improvement Reduce dose to 200 mg/m2
No improvement Discontinue cetuximab
Third occurrence Delay infusion 1 to 2 weeks Improvement Reduce dose to 150 mg/m2
No improvement Discontinue cetuximab
Fourth occurrence Discontinue cetuximab    
Erbitux (cetuximab) package insert, ImClone LLC, August, 2013.
Graphic 58603 Version 7.0